NKGen Biotech’s proprietary SNK autologous and allogeneic cellular immunotherapies achieve high-fold cell expansion of highly activated and pure natural killer (NK) cells.
NKGen Biotech’s innovative and unique NK cell immunotherapy, SNK, involves the infusion of one’s own activated NK cells (autologous SNK01) or donor NK cells (SNK02) into the body with the goal to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses highly pure NK cells harvested from the patient’s, or donors’ blood, activated and infused back into the patient’s body.
Autologous SNK stands out from other available therapies because it is from the patient’s own blood, not genetically modified, and has less chance of side effects than other therapies such as chimeric antigen receptor T cell (CAR-T) treatments.
SNK has a broad therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases.
